A preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine

Abstract: In experimental conditions, it has been demonstrated that vaccine efficacy and the toxicity is depending on cytokine-induced immunoinflammatory response, and that they may be modulate through a neuroimmune approach, which neuroendocrine agents, such as the pineal hormone melatonin (MLT) a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lissoni, Paolo, Rovelli, Franco, Messina, Giusy, Monzon, Alejandra, Colciago, Massimo, Valentini, Agnese, Di Fede, Giuseppe, Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: Open Access Text Pvt, Ltd. 2022
Materias:
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/13639
Aporte de:
id I33-R139123456789-13639
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic VACUNACION
COVID-19
INMUNOLOGIA
NEUROPROTECCION
MELATONINA
spellingShingle VACUNACION
COVID-19
INMUNOLOGIA
NEUROPROTECCION
MELATONINA
Lissoni, Paolo
Rovelli, Franco
Messina, Giusy
Monzon, Alejandra
Colciago, Massimo
Valentini, Agnese
Di Fede, Giuseppe
Cardinali, Daniel Pedro
A preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine
topic_facet VACUNACION
COVID-19
INMUNOLOGIA
NEUROPROTECCION
MELATONINA
description Abstract: In experimental conditions, it has been demonstrated that vaccine efficacy and the toxicity is depending on cytokine-induced immunoinflammatory response, and that they may be modulate through a neuroimmune approach, which neuroendocrine agents, such as the pineal hormone melatonin (MLT) and the enzymatic product of ACE2, the angiotensin 1-7 (Ang 1-7). On these bases, a preliminary study was planned to evaluate the influence of an oral peri-vaccination regimen with MLT plus Ang 1-7 on the subjective safety of Covid19 Pfizer-BioNTech (PF) and AstraZeneca (AZ) vaccines. The study included 60 subjects, 30 of whom received PF vaccine, while the other 30 subjects were treated by AZ vaccine. Both groups of subjects were randomized to receive the only vaccine or vaccine plus Ang 1-7 (0.5 mg/day in the morning) and MLT (10 mg/day in the evening) regimen, starting 3 days prior to vaccine and for the successive 4 days. The percentage of episodes of fever higher than 38°C, asthenia and myalgia were significantly reduced by the concomitant administration of Ang 1-7 plus MLT. This preliminary study shows the possibility to modulate the safety of Covid19 vaccine through a neuroimmune approach consisting of Ang 1-7 plus MLT. Further studies will be required to confirm these data, and to evaluate the impact not only on the safety, but also on the efficacy of Covid19 vaccination..
format Artículo
author Lissoni, Paolo
Rovelli, Franco
Messina, Giusy
Monzon, Alejandra
Colciago, Massimo
Valentini, Agnese
Di Fede, Giuseppe
Cardinali, Daniel Pedro
author_facet Lissoni, Paolo
Rovelli, Franco
Messina, Giusy
Monzon, Alejandra
Colciago, Massimo
Valentini, Agnese
Di Fede, Giuseppe
Cardinali, Daniel Pedro
author_sort Lissoni, Paolo
title A preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine
title_short A preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine
title_full A preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine
title_fullStr A preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine
title_full_unstemmed A preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine
title_sort preliminar study of a neuroimmune regimen with lowdose angiotensin 1-7 plus melatonin to improve the safety of covid 19 vaccine
publisher Open Access Text Pvt, Ltd.
publishDate 2022
url https://repositorio.uca.edu.ar/handle/123456789/13639
work_keys_str_mv AT lissonipaolo apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT rovellifranco apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT messinagiusy apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT monzonalejandra apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT colciagomassimo apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT valentiniagnese apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT difedegiuseppe apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT cardinalidanielpedro apreliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT lissonipaolo preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT rovellifranco preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT messinagiusy preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT monzonalejandra preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT colciagomassimo preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT valentiniagnese preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT difedegiuseppe preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
AT cardinalidanielpedro preliminarstudyofaneuroimmuneregimenwithlowdoseangiotensin17plusmelatonintoimprovethesafetyofcovid19vaccine
bdutipo_str Repositorios
_version_ 1764820526372487168